The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Procept BioRobotics Corp (NASDAQ: PRCT) closed at $40.17 in the last session, down -0.42% from day before closing price of $40.34. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 0.77 million shares were traded. PRCT stock price reached its highest trading level at $40.8 during the session, while it also had its lowest trading level at $40.0.
Ratios:
We take a closer look at PRCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 9.20. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on July 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $105.Morgan Stanley initiated its Overweight rating on December 02, 2024, with a $105 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when MOLL FREDERIC H bought 20,000 shares for $39.26 per share. The transaction valued at 785,138 led to the insider holds 863,159 shares of the business.
Desai Antal Rohit sold 25,000 shares of PRCT for $1,597,711 on Jun 10 ’25. The Director now owns 64,363 shares after completing the transaction at $63.91 per share. On Jun 11 ’25, another insider, Desai Antal Rohit, who serves as the Director of the company, sold 25,000 shares for $63.38 each. As a result, the insider received 1,584,525 and left with 39,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 2234894080 and an Enterprise Value of 2011545728. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.13 while its Price-to-Book (P/B) ratio in mrq is 5.79. Its current Enterprise Value per Revenue stands at 7.316 whereas that against EBITDA is -23.412.
Stock Price History:
The Beta on a monthly basis for PRCT is 1.01, which has changed by -0.46482813 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $103.81, while it has fallen to a 52-week low of $37.12. The 50-Day Moving Average of the stock is -20.68%, while the 200-Day Moving Average is calculated to be -37.66%.
Shares Statistics:
According to the various share statistics, PRCT traded on average about 1.07M shares per day over the past 3-months and 821120 shares per day over the past 10 days. A total of 55.58M shares are outstanding, with a floating share count of 52.83M. Insiders hold about 5.04% of the company’s shares, while institutions hold 96.28% stake in the company. Shares short for PRCT as of 1755216000 were 8067967 with a Short Ratio of 7.54, compared to 1752537600 on 6823424. Therefore, it implies a Short% of Shares Outstanding of 8067967 and a Short% of Float of 17.19.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 9.0 analysts currently analyzing and rating the stock of Procept BioRobotics Corp (PRCT).The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.23 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.45 and -$1.51 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$0.94, with 9.0 analysts recommending between -$0.41 and -$1.3.
Revenue Estimates
According to 11 analysts, the current quarter’s revenue is expected to be $80.78M. It ranges from a high estimate of $82.05M to a low estimate of $79.63M. As of the current estimate, Procept BioRobotics Corp’s year-ago sales were $58.37MFor the next quarter, 11 analysts are estimating revenue of $96.43M. There is a high estimate of $97.37M for the next quarter, whereas the lowest estimate is $95.37M.
A total of 12 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $337.31M, while the lowest revenue estimate was $325.35M, resulting in an average revenue estimate of $326.53M. In the same quarter a year ago, actual revenue was $224.5MBased on 12 analysts’ estimates, the company’s revenue will be $426.85M in the next fiscal year. The high estimate is $433.5M and the low estimate is $416.1M.
